Название продукции:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
IUPAC Name:4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]aniline
- CAS：2448173-20-2
- Молекулярная формула：C16H17N5O
- Чистота：95%+
- Номер в каталоге：CM1045041
- Молекулярная масса：295.35
| Упаковочная единица |
Доступно для заказа |
Цена ($) |
Количество |
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:2448173-20-2
- Молекулярная формула:C16H17N5O
- Точка плавления:-
- Smiles-код:NC1=CC=C(C=C1)C1=CC2=C(N=CN=C2N1)N1CCOCC1
- Плотность:
- Номер в каталоге:CM1045041
- Молекулярная масса:295.35
- Точка кипения:
- Номер Mdl:
- Хранение:
Category Infos
- Pyrrolopyrimidines
- Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.
Column Infos
- BMF-219
- Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.
Поиск 
+86 21 5895 0110 
